ANI Pharmaceuticals, Inc. announced the launch of its Prucalopride Tablets, a generic version of the drug Motegrity®, following final FDA approval of their Abbreviated New Drug Application.

ANI Pharmaceuticals, Inc., a diversified biopharmaceutical company, announced that following final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application ...

Findings from a multicenter, randomized, placebo-controlled, phase III study have demonstrated the beneficial effects of the 5-hydroxytryptamine 4 receptor agonist, prucalopride, for chronic ...

(RTTNews) - ANI Pharmaceuticals, Inc. (ANIP) announced Thursday the launch of Prucalopride Tablets, which is the generic version of the reference listed drug (RLD) Motegrity. The launch follows ...

02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its ...

ANI’s Prucalopride Tablets is the generic version of the reference listed drug (RLD) Motegrity®. "We are delighted to build momentum early in 2025 with the approval of the first generic for ...

02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its ...